The pharmaceutical giant raked in $40.1 billion in global sales in 2017, an increase of 1% from the year before. Merck’s superstar cancer immunotherapy drug Keytruda has continued to be the big performer; it alone brought in $1.46 billion in the first quarter of this year–an increase of 150% from the same time period last year. Success has been a mixed blessing, however. Keytruda now plays an outsize role in Merck’s portfolio, responsible for about 15% of the company’s sales. Moreover, plans to expand the drug’s applications have hit a snag: A collaboration with the biotech research firm Incyte to combine the drug with another experimental therapy has been recently halted.
Looking for leads, investment insights, or competitive intelligence?
News about Merck
Trump is pleased with the result of his blast.
GSK's new shingles vaccine Shingrix is in short supply in the U.S.
The story of Alzheimer's drug development is one of perpetual tragedy and setbacks.
The alliance of nearly 500 chief executives reports a successful first year in addressing inclusion at their firms and has big goals ahead.